| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184601 | Gynecologic Oncology | 2012 | 7 Pages |
Abstract
⺠Analysis of a randomized trial in ovarian cancer, neither erythropoietin nor granulocyte colony stimulating agents had a survival impact. ⺠Adjustments were made for factors known to impact survival; stage, residual tumor, and performance status. ⺠Landmark analysis was employed since patients may have received cytokine at any time during chemotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Frederick B. Stehman, Mark F. Brady, J. Tate Thigpen, Emma C. Rossi, Robert A. Burger,